Trial
NCT02241785
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Relapsing Multiple Sclerosis
Intervention
natalizumab
Why stopped
Business Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-05